Research
Hormonal
Moderate alcohol consumption may confer cardiovascular protection in Type 2 Diabetes patients, but chronic consumption (even low/moderate) may trigger or worsen T2DM and raise blood pressure.
The effect of alcohol on diabetes is mixed. While moderate drinking might lower heart disease risk, it can also raise blood pressure and worsen diabetes. If you drink, do so in moderation. If you have uncontrolled diabetes or high blood pressure, it may be safer to avoid alcohol. Consult your doctor.
ModerateQualifiesMEDIUM confidence
The consumption of a moderate amount of alcohol confers cardiovascular protection and has been associated with a decreased incidence of heart disease in patients with DM... However, a meta-analysis of 38 observational studies suggests that previous works overestimate the risk reductions... or that chronic alcohol consumption, even when it is low or moderate, may trigger the progression or development of T2DM.
Why this rating
The paper cites conflicting meta-analyses and observational studies.
Source
Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients
Iciar Martín-Timón et al. · European Medical Journal · 2016
DOI 10.33590/emj/10313882
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs) are the preferred antihypertensive treatments for diabetic patients due to renal protection and lack of adverse metabolic effects.Good
- Combining aerobic and resistance exercise produces greater cardiovascular benefits in Type 2 Diabetes patients than performing either modality in isolation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →